Avanços Médicos: Marcadores Tumorais Versus Carcinoma de Mama
DOI:
https://doi.org/10.32635/2176-9745.RBC.1995v41n1.2922Palabras clave:
Marcadores Tumorais, Carcinoma de MamaResumen
Os autores propõe uma revisão sobre o Marcador Tumoral CA 15.3 e o Carcinoma de mama. Entre muitos marcadores já testados nesta doença, o CA 15.3 é o que tem apresentado os melhores resultados. Contudo não podemos considerar o CA 15.3 como ideal, por sua baixa sensibilidade para doença precoce. Muitos estudos ainda devem ser feitos sobre o tema câncer de mama X marcadores tumorais.
Descargas
Citas
SAFI F; KOHLER I; ROTTINGER E; SUHE P; BEGER HG. Comparison of CA 15.3 and CEA in diagnosis and monitoring of breast cancer. lnt J Biol Markers, 1989; 4: 207-14. DOI: https://doi.org/10.1177/172460088900400405
Instituto Nacional do Câncer - Ministério da Saúde. Registro Nacional de Patologia Tumoral. Diagnóstico de Câncer no Brasil 1981/85.
BOCCARDO E; BOMBARDIERI E; ZANARDI S; VALENTI G; ZANABONI F; VALTOLINA M; SEREGNI E; CRIPPA F. Preliminary study on serun leveis of mucinous like câncer antigen (MCA) in patients with breast disease: comparison with CEA. IntJ Biol markers 1991; 6:12-20. DOI: https://doi.org/10.1177/172460089100600103
LOPRINZI Cl_; TORMEY D; RASMUSSEN P; FALKASON G; DAVIS TE; FALKSON HC; CHANG AYC. Prospective evalution of carcinoembionic antigen leveIs and alternating chemotherapeutic regimes in metastatic breast cancer. J Clin Oncol 1986; 4: 46-56. DOI: https://doi.org/10.1200/JCO.1986.4.1.46
MUGHALAW; HORTOBAGYI GN; FRITSCHE HA; BUZDAR AU; YAP HY; BLUMENSCHEIN GR. Serial plasma carcinoembrionic antigen measurement during treatment of metastatic breast cancer. JAMA 1983; 249: 1881-1886. DOI: https://doi.org/10.1001/jama.249.14.1881
FRANCINI G; MONTAGNANI M; PETRIOLI R; PAFFETTI P. MARSILI 5; LEONE V. Comparison between CEA, TPA, CA 15.3 and Hydroxyproline, alkaline phosphatase, whole body retention of 99m-Tc in the foilow-up of bone metastases in breast cancer. Int J Biol Markers 1990; 5: 65-72. DOI: https://doi.org/10.1177/172460089000500203
CAPONIGRO F; IAFFAIOLI RV; PAGLIARULO C; PLACIDE S; FRASCI G; UNGARO B; MATANO E; BIANCOAR. CA 15.3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembionic antigen (CEA). Int J Biol Markers 1990; 5: 73-6. DOI: https://doi.org/10.1177/172460089000500204
BHATAVDEKAR JM; TRIVEDI SN; SHAH NG; PATEL DD; KARELIA NH; SHUKLA MK; GHOSH N; VORA HH. Comparison of prolactin, CA 15.3 and TPA in breast carcinoma. nt J Biol Markers, 1989; 4: 150-6. DOI: https://doi.org/10.1177/172460088900400304
BIRKMAYER JGD; PALETTA B. New strategies for follow up of breast cancer patients using CEA, TPA, CA 15.3 and CP 50. Human Tumor Markers 1987: 621 -30. DOI: https://doi.org/10.1515/9783110846515-045
MOLINA R; FILELLA X; MENGUAL P; PRATS M; ZANON G; DANIELS M; BALLESTA AM. MOA in patients with breast cancer: correlation with CEA and CA 15.3 Int J Biol Markers 1990; 5: 14-21. DOI: https://doi.org/10.1177/172460089000500103
SORIANO A; ALLENDE MT; VIZOSO F; GGARCIA JF; VIVANCIO J; RUIBAL A. MOA and CA 15.3 serum leveis in non-malignant diseases. Some preliminary results. Letter to the Editor. Int J Biol Markers 1990; 5: 46-47. DOI: https://doi.org/10.1177/172460089000500110
JENSEN JL; MACLEAN GD; SURESH MR; ALMEIDA A; JETTE D; LLOYD 5; BODNAR D; KRANTZ M; LONGENECKER BM. Possible utility of serum determinations of CA 125 and CA 27-29 in breast cancer management. Int J Biol Markers 1990; 6:1-6. DOI: https://doi.org/10.1177/172460089100600101
OMAR YT; BEHBEHANI AE; AL-NAQEEB N; MOTAWY MM; FOUDEH MO; AWWAD AH; NASRALLA MY; SZYMENDERA. Preoperative and longitudinal serum levels of CA 125 and CA 15.3 in patients with breast cancer. Int J Biol Markers 1989; 4: 81-6. DOI: https://doi.org/10.1177/172460088900400204
TORRES M; JIMENEZ-HEFFERNAN A; GARCIA A; VALVERDE A; MATEO A. CA 549 and SP2: new tumor markers in breast cancer. Letter to the Editor. Int J Biol Markers 1990; 5: 97-98. DOI: https://doi.org/10.1177/172460089000500209
DNISTRIAN AM; SCHWATZ MK; GREENBERG EJ; SMITH CA; DORSA R; SCHWARTZ DO. CA 549 as a marker in breast cancer. lntJ Biol Markers 1991; 6:139-43. DOI: https://doi.org/10.1177/172460089100600301
KUTE TE; ZBIERANSKI N; LONG R; POELING K. Proteases and otherprognostic markers in node negative breast cancer; 14th Annual San Antonio Breast Oancer Symposium 1991; Abstract 183.
SCARAMUZZI M; AMOROTTI O; DE PALMA M; FALCHI AM; BALDINI E; DE MARIA D; CASOLO P. Olinical evaluation of CA 15.3 in the post-operatíve foilow-up of breast cancer patients. Int J Biol Markers 1990; 5: 22-26. DOI: https://doi.org/10.1177/172460089000500104
SCARAMUZZI M; AMOROTTI C; DE PALMA M; FALCHI AM; DE MARIA D; CASOLO P. Prognostic significance of CA 15.3 in metastatic breast cancer. Int J Biol Markers 1990; 5: 35-37. DOI: https://doi.org/10.1177/172460089000500107
RHODE PS; SCHULZ KD; STURM G; FRIOK AR; PRINTZ H. CA 15.3 as a tumor marker in breast cancer. Int J Biol markers 1987; 2:135-42. DOI: https://doi.org/10.1177/172460088700200301
VIZOSO F; ALLENDE MT; FUEYO A; VIGAL G; MORAN MG; RUIBAL A. CA 15.3 behavior in cystic breast disease. Letter to the editor. Int J Biol Markers 1989; 4: 181-182. DOI: https://doi.org/10.1177/172460088900400309
BYRNE J; HORGAN P0; ENGLAND S; CALLAGHAN J; GIVEN HF. An evaluation of the usefulness of primary tumour expression of MOA and CA 15.3 as prognostic indicators in breast carcinoma. Eur J of Surg Oncol 1992; 28 (3): 230-34.
HAYES DF; ZURAWSKI VR; KUFE DW. Comparison of circulating CA 15.3 and carcinoembionic antigen leveis in patients with breast cancer. J Olin Oncol 1986; 4: 1542-50. DOI: https://doi.org/10.1200/JCO.1986.4.10.1542
OOLLAZOS; GENOLLA J; RUIBAL A. CA 15.3 in nonmalignant liver diseases. Int J Biol Markers 1991; 6:188-92. DOI: https://doi.org/10.1177/172460089100600309
ZANCO P; ROTA G; SPORTIELLO V; BORSATO N; FERLIN G. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques. Int J Biol Markers 1989; 4: 103-105. DOI: https://doi.org/10.1177/172460088900400207
